QDEL at a glance
QuidelOrtho Corp (QDEL, SEC CIK 1906324) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as October 19, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 28, 2025 (FY2025), QuidelOrtho Corp (QDEL) reported revenue of $2.7 billion (down 1.9% from FY2024) and a net loss of $1.1 billion. Diluted EPS was -$16.69.
- As of September 30, 2026, 26 institutional investment managers tracked by SignalX reported holding QuidelOrtho Corp (QDEL) shares worth $357.0 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.7B
- −1.9% vs prior year
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 26 funds
- $357.0M · −2 vs prior quarter
- Latest 8-K
- Nov 3, 2026
- Item 2.02 · Item 5.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 28, 2025
Business Overview
- Core business model: global diagnostics provider specializing in immunoassay, molecular testing, clinical chemistry, transfusion medicine, and POC solutions
- Initiated wind-down of U.S. donor screening portfolio (VIP platform, microplate assays) starting Feb 2024, expected substantially complete by mid-2026
- New emphasis on advancing digital solutions with launch of QuidelOrtho RESULTS MANAGER and planned 2026 releases of automation and informatics products
- R&D spend $186.2M in 2025, down from $218.7M in 2024, reflecting project phase transitions and continued innovation investment
- Customer service innovation highlighted by being first medical device company awarded global ISO Excellence Services Label in EMEA region
Risk Factors
- Legal/regulatory risk: FDA EUA approvals and compliance with anti-bribery and data privacy laws impacting product commercialization and operations
- Geopolitical/macro risk: April 2025 U.S. tariffs on imports from U.K., Canada, Mexico, China causing incremental supply chain and shipping costs
- Operational/supply chain risk: Concentration in California facilities near earthquake/fire faults posing disruption risk to manufacturing and product delivery
- Competitive risk: Distributors developing own competitive products and exclusive agreements with rivals threatening key sales channels
- Financial risk: Customer concentration with significant revenues from few distributors; loss would materially disrupt sales and financial results
Management Discussion & Analysis
- Revenue $2,730.2M FY25, down 2% YoY from $2,782.9M; FY24 down 7% YoY from $2,997.8M, COVID-19 product declines primary driver
- Operating margin approx. 20.1% FY25 (Operating expenses $1,488.9M = 54.5% of revenue), cost of sales 53.3% vs 53.8% in FY24; margin benefit from cost savings initiatives
- Best segment growth: EMEA revenue up 7% to $360.7M, Adjusted EBITDA up 78% to $82.6M; worst segment: Donor Screening revenue down 54% to $52.6M due to U.S. wind-down
- Operating cash flow pressures from restructuring charges: Restructuring charges $263.6M in FY25 vs $127.2M in FY24; buybacks/dividends details not provided; capital spending not detailed
- Outlook cautious: Ongoing COVID/endemic dynamics, competitive pressures, pricing pressures, geopolitical tariffs risks; restructuring and strategic refocus ongoing to improve financials
AI summary of the QDEL 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 27, 2026
Management Discussion & Analysis
- Q3 revenue $618.9M, down 12% YoY from $699.9M
- Cost of sales margin 53.2% vs 52.1% YoY, implying gross margin 46.8% vs 47.9%
- Best line Immunohematology $142.0M, flat YoY; worst Donor Screening $1.7M, down 88% from $14.7M
- Cash $166.4M, down $3.4M; operating cash flow used $124.0M through nine months
- Outlook: weaker respiratory season may persist; China pricing changes and tariffs remain headwinds, with over $80M annual savings targeted for 2027
Risk Factors
- No material changes to risk factors since the Annual Report
- Significant indebtedness, potentially limiting financial flexibility
- Dependence on product development and commercialization success
- Healthcare regulatory approvals and compliance requirements
- Intense competition in in-vitro diagnostics markets
AI summary of the QDEL 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results for quarter ended September 27, 2026 announced
- Earnings conference call scheduled November 3, 2026 at 2:00 p.m. Pacific Time
Item 5.02: Departure/Appointment of Directors or Principal Officers
- New operating model organized around Core Diagnostics and Point of Care Diagnostics
- Jonathan Siegrist appointed Head of Point of Care Diagnostics, Bryan Hanson Head of Core Diagnostics, effective November 9, 2026
Item EX-99.1: Item EX-99.1
- Q3 revenue $618.9M, down 11.6%, driven by respiratory, China, and U.S. Donor Screening weakness
- Underlying revenue excluding those businesses grew 2.3% reported and 3.0% constant currency
Item 1.01: Entry into a Material Definitive Agreement
- Covenant relief through September 30, 2029, signaling elevated leverage or reduced earnings pressure
- Leverage cap eases to 5.50x through July 2, 2028, then tightens to 4.25x from September 30, 2029
Item 2.02: Results of Operations and Financial Condition
- Q2 FY2026 results covered quarter ended June 28, 2026
- Press release furnished as Exhibit 99.1, containing the financial results and management commentary
Item EX-99.1: Item EX-99.1
- Q2 revenue $630.9M, up 2.8% reported and 1.9% constant currency, with 6.1% growth excluding China
- Point of Care revenue $108.2M, up 16.3%, while Labs excluding China grew 9.0%
AI summaries of QDEL 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for QDEL
Don't miss the next QDEL filing
- Alerts as it files. A push when QDEL files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut QDEL, by share count.
- Ask anything. An AI agent that reads every QDEL filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Siegrist Jonathan Philip | M | Oct 15, 2026 | 18,657 | - |
| Siegrist Jonathan Philip | F | Oct 15, 2026 | 6,695 | $13.91 |
| Siegrist Jonathan Philip | M | Oct 15, 2026 | 18,657 | - |
| Bowman Ronald Lee | F | Sep 15, 2026 | 921 | $10.63 |
| Bowman Ronald Lee | M | Sep 15, 2026 | 2,566 | - |
| Bowman Ronald Lee | M | Sep 15, 2026 | 2,566 | - |
| Hanson Bryan Michael | M | Aug 15, 2026 | 446 | - |
| Hanson Bryan Michael | M | Aug 15, 2026 | 446 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.8B | $2.7B |
| Operating Income | - | -$2.0B | -$919.2M |
| Net Income | -$10.1M | -$2.1B | -$1.1B |
| Op. Margin | - | -70.5% | -33.7% |
| Net Margin | - | -73.7% | -41.5% |
| Balance Sheet | |||
| Total Assets | $8.6B | $6.4B | $5.8B |
| Equity | - | $3.0B | $1.9B |
| ROE | - | -68.8% | -58.9% |
| Per Share | |||
| EPS | $-0.15 | $-30.54 | $-16.69 |
| Cash Flow | |||
| Operating CF | - | $83.0M | $105.2M |
| CapEx | $209.3M | $195.1M | $188.2M |
Source: XBRL data in QuidelOrtho Corp (QDEL)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate QDEL share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 26 | $357.0M |
| Q2 2026 | 28 | $709.9M |
| Q1 2026 | 28 | $650.5M |
| Q4 2025 | 27 | $1.10B |
| Q3 2025 | 27 | $1.08B |
| Q2 2025 | 26 | $1.05B |
| Q1 2025 | 25 | $903.5M |
| Q4 2024 | 23 | $938.6M |
- Goldman Sachs Group+1.17M (+110%)
- Citigroup+294.6K (+849%)
- Morgan Stanley+271.4K (+16%)
- Invesco Ltd+131.4K (+4%)
- Bank of America Corp+69.9K (+69%)
- Vanguard Portfolio Management LLC−499.7K (-12%)
- Dimensional Fund Advisors−414.9K (-33%)
- AQR Capital Management−339.3K (-37%)
- Millennium Management−129.6K (-18%)
- BlackRock−59.5K (-1%)
- Citadel Advisors LLC+283.6K
- IMMERSION CORP+65.6K
- FMR LLC (Fidelity)−7.36M
- Franklin Resources−38.7K
- Two Sigma Investments−17.4K
- Raymond James Financial−13.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 210 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
QDEL filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 10-Q | Nov 4, 2026 | Sep 27, 2026 | Analysis | |
| 8-K | Nov 3, 2026 | - | Analysis | - |
| 4 | Oct 19, 2026 | - | - | - |
| 8-K | Sep 23, 2026 | - | Analysis | - |
| 4 | Sep 17, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| SC 13G | Aug 13, 2026 | - | - | |
| 10-Q | Aug 7, 2026 | Jun 28, 2026 | Analysis | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 4 | Jul 16, 2026 | - | - | - |
| SC 13G | Jul 8, 2026 | - | - | |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 8-K | Jun 23, 2026 | - | Analysis | - |
| 8-K | Jun 16, 2026 | - | Analysis | - |
| 4 | Jun 9, 2026 | - | - | |
| 4 | Jun 9, 2026 | - | - |
Related Health Care companies
- TKNO · Alpha Teknova, Inc.In Vitro & In Vivo Diagnostic Substances
- CLDX · Celldex Therapeutics, Inc.In Vitro & In Vivo Diagnostic Substances
- IDXX · Idexx LaboratoriesIn Vitro & In Vivo Diagnostic Substances
- NTLA · Intellia Therapeutics, Inc.In Vitro & In Vivo Diagnostic Substances
- LNTH · Lantheus Holdings, Inc.In Vitro & In Vivo Diagnostic Substances
- MYGN · MYRIAD GENETICS INCIn Vitro & In Vivo Diagnostic Substances
- NEOG · NEOGEN CORPIn Vitro & In Vivo Diagnostic Substances
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
QDEL SEC filings: frequently asked questions
Which institutions hold QDEL stock?
As of September 30, 2026, the largest QuidelOrtho Corp (QDEL) holders among the 13F filers tracked by SignalX were BlackRock ($117.4 million), Vanguard Portfolio Management LLC ($38.3 million), Invesco Ltd ($38.0 million), State Street Corp ($31.9 million), Vanguard Capital Management LLC ($31.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was QDEL's revenue in fiscal year 2025?
For the fiscal year ended December 28, 2025 (FY2025), QuidelOrtho Corp (QDEL) reported revenue of $2.7 billion (down 1.9% from FY2024) and a net loss of $1.1 billion. Diluted EPS was -$16.69. The figures come from the XBRL data in the 10-K.
What are the main risks in QDEL's latest 10-K?
In the 10-K filed February 19, 2026, QuidelOrtho Corp (QDEL) flagged: Legal/regulatory risk: FDA EUA approvals and compliance with anti-bribery and data privacy laws impacting product commercialization and operations. Geopolitical/macro risk: April 2025 U.S. tariffs on imports from U.K., Canada, Mexico, China causing incremental supply chain and shipping costs. (AI summary of the Risk Factors section.)
What did QDEL report in its latest 8-K?
QuidelOrtho Corp (QDEL) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 5.02 (Departure/Appointment of Directors or Principal Officers). Q3 2026 results for quarter ended September 27, 2026 announced.
What are the latest QDEL SEC filings?
QuidelOrtho Corp (QDEL) filed its latest 10-K annual report on February 19, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on October 19, 2026.
What is QDEL's SEC CIK number?
QuidelOrtho Corp (QDEL)'s SEC Central Index Key (CIK) is 1906324. EDGAR lists every QDEL filing under that number.
Ask anything about QDEL
The research agent reads QDEL's filings, financials, insider trades and 13F holders, then answers with sources.